
Solid Bioscience Reports Positive Early Data from Duchenne Gene Therapy Trial
Solid Biosciences reported recent positive data in developing their gene therapy candidate SGT-003. The phase 1/2 INSPIRE DUCHENNE trial results demonstrated that SGT-003 showed an average microdystrophin expression of 110% in the first three participants. In a news release earlier this month, the Charlestown, Massachusetts, company says that treatment with SGT-003 led to significant improvements in muscle health biomarkers.Duchenne muscular dystrophy is a genetic condition that leads to muscle...